In this Issue:
Gefitinib vs. erlotinib in advanced lung adenoma
Afatinib vs. chemotherapy in EGFR mutant NSCLC
Clinical activity of AZD9291
First in-human evaluation of CO-1686
Erlotinib + bevacizumab for advanced EGFR activating NSCLC
Crizotinib in advanced ALK-positive NSCLC
Crizotinib in advanced c-MET
amplified NSCLC
First line MK-3475 in advanced NSCLC
Adjuvant erlotinib in advanced EGFR positive NSCLC
PCI ineffective in extensive disease SCLC
Thoracic RT in extensive disease SCLC
Arginine deprivation in MPM
Front line antimesothelin vaccine for MPM
Please login below to download this issue (PDF)